Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain.
It is without dispute that the treatment of neuropathic pain is an area of largely unmet medical need. Available analgesics, such as morphine, either have minimal effects in neuropathic pain patients, or are not always well tolerated due to concurrent adverse effects. The chronicity of neuropathic pain is thought to be related to many neurochemical changes in the dorsal root ganglia (DRG) and spinal cord, including a reduction in the retrograde transport of nerve growth factor (NGF). In this study, we have determined the ability of chronic intrathecal (i.t.) infusion of NGF to reverse neuropathic pain symptoms and to restore morphine's effectiveness in an animal model of neuropathic pain. Seven days after sciatic nerve constriction injury, NGF was administered to the spinal cord by continuous infusion (125 ng/microl/h) via osmotic pumps attached to chronically implanted i.t. catheters. Spinal infusion of NGF did not affect the expression of tactile allodynia or thermal (hot) hyperalgesia in neuropathic rats, although it significantly increased cold water responses frequency at day 14. Following infusion of vehicle, i.t. morphine (20 microg) was ineffective in altering somatosensory thresholds in neuropathic rats. In contrast, morphine substantially attenuated the neuropathy-induced warm and cold hyperalgesia, as well as tactile allodynia, in neuropathic rats chronically infused with i.t. NGF. In addition, we demonstrate that i.t. morphine-induced antinociception was augmented by a cholecystokinin (CCK) antagonist in animals chronically infused with i.t. antibodies directed against NGF. We hypothesize that NGF is critical in maintaining neurochemical homeostasis in the spinal cord of nociceptive neurons, and that supplementation may be beneficial in restoring and/or maintaining opioid analgesia in chronic pain conditions resulting from traumatic nerve injury.
Cahill
Catherine M
CM
Department of Pharmacology and Toxicology, Queen's University, Kingston, ON, Canada.
Dray
Andy
A
Coderre
Terence J
TJ
D000701:Analgesics, Opioid / Q000627:therapeutic use; D000818:Animals; D003080:Cold Temperature / Q000009:adverse effects; D004195:Disease Models, Animal; D006358:Hot Temperature / Q000009:adverse effects; D007278:Injections, Spinal; D008297:Male; D009020:Morphine / Q000627:therapeutic use*; D020932:Nerve Growth Factor / Q000008:administration & dosage* / Q000502:physiology; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D010812:Physical Stimulation / Q000379:methods; D051381:Rats; D020318:Rats, Long-Evans; D020426:Sciatic Neuropathy / Q000188:drug therapy* / Q000503:physiopathology
D000701:Analgesics, Opioid; D009020:Morphine; D020932:Nerve Growth Factor